|
Instem PLC - Staffordshire, England-based life science software - Extends contract with a ‘global contract research organisation’, worth about $1.4 million, for over 900 additional users of Instem’s Provantis non-clinical study management platform. As a result, the CRO will now have about 7,400 Provantis users. ‘The significantly expanded number of users of the Provantis platform will help the client to meet demand for its non-clinical study services, which continue to grow across the pharmaceutical, biotech and agrochemical markets’.
Chief Executive Phil Reason says: ‘We are delighted to have further strengthened our long-standing relationship with the client. This endorsement further highlights the strength of our offering, sector standing and the buoyant industry demand for non-clinical studies, which has generated software license growth from many of our CRO clients.’
Current stock price: 706.00 pence, up 0.9% on Thursday afternoon in London
12-month change: down 18%
By Xindi Wei, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.
|
